INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Unspecified Childhood Solid Tumor, Protocol SpecificInterventions:   Drug: ruxolitinib phosphate;   Other: laboratory biomarker analysis;   Other: pharmacological studySponsors:   Children's Oncology Group;   National Cancer Institute (NCI)Completed - verified October 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials